is a biopharmaceutical company focused on the development of
novel treatments for B-cell malignancies and autoimmune diseases.
Click for full image >>
TG Therapeutics Recaps Schedule of Data Presentations at the 58th American Society of Hematology Annual Meeting
TG Therapeutics Announces Positive DSMB Recommendation for Continuation of the UNITY-CLL Phase 3 Trial (Evaluating TG-1101 +TGR-1202 Compared to Obinutuzumab + Chlorambucil)
2 Gansevoort Street, 9th Floor, New York NY 10014 - P:212.554.4484 - Email Us
Web Site Development by Tidal Media Group